for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Seres Therapeutics Inc

MCRB.OQ

Latest Trade

4.01USD

Change

0.15(+3.89%)

Volume

1,274,335

Today's Range

3.85

 - 

4.07

52 Week Range

2.02

 - 

8.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.86
Open
3.86
Volume
1,274,335
3M AVG Volume
11.05
Today's High
4.07
Today's Low
3.85
52 Week High
8.99
52 Week Low
2.02
Shares Out (MIL)
69.91
Market Cap (MIL)
280.35
Forward P/E
-2.70
Dividend (Yield %)
--

Latest Developments

More

Seres Therapeutics Reports Second Quarter Financial Results And Provides Progress Update

Seres Therapeutics Issues Statement Regarding U.S. FDA Safety Alert Related To Use Of Fecal Microbiota Transplantation

MTIG - Working With FDA For Evaluation Of Safety Parameters Related To Microbiota-Based Therapeutic Products

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Seres Therapeutics Inc

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

Industry

Biotechnology & Drugs

Contact Info

200 Sidney St

+1.617.9459626

http://serestherapeutics.com/

Executive Leadership

Roger J. Pomerantz

Chairman of the Board

Eric D. Shaff

President, Chief Executive Officer, Director

Marcus Chapman

Principal Financial and Accounting Officer, Vice President - Finance

John G. Aunins

Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing

Matthew R. Henn

Executive Vice President, Chief Scientific Officer

Key Stats

2.00 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.300

2017

-2.210

2018

-2.430

2019(E)

-1.485
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.09
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-78.64
Return on Equity (TTM)
-56.14

Latest News

BRIEF-Seres Therapeutics Announces Initiation Of Ser-287 Phase 2B Eco-Reset Clinical Study For Ulcerative Colitis

* SERES THERAPEUTICS ANNOUNCES INITIATION OF SER-287 PHASE 2B ECO-RESET CLINICAL STUDY FOR ULCERATIVE COLITIS

BRIEF-Seres Therapeutics Reports Qtrly Loss Per Share Of $0.69

* SERES THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES

BRIEF-Nestle Health Science Us Holdings, Inc Reports 16.97 Pct Stake In Seres Therapeutics Inc

* Nestle Health Science Us Holdings, Inc Reports 16.97 Pct Stake In Seres Therapeutics Inc As Of April 10, 2018 - SEC Filing Source text (https://bit.ly/2GSzKlq) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Seres Therapeutics Qtrly Net Loss Of $29.0 Mln Vs $25.3 Mln

* SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

BRIEF-Seres Therapeutics Says Has Cash, Cash Equivalents And Investments Of $171.3 Mln

* SERES THERAPEUTICS SAYS HAS CASH, CASH EQUIVALENTS AND INVESTMENTS OF $171.3 MILLION, AS OF SEPT 30, 2017 - SEC FILING Source text: (http://bit.ly/2qFSBN0) Further company coverage:

BRIEF-Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis

* SERES THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SER-287 IN TREATMENT OF PEDIATRIC ULCERATIVE COLITIS

BRIEF-Seres Therapeutics Q2 net loss $28 million

* Seres therapeutics reports second quarter 2017 financial results and provides update on operational progress

BRIEF-Seres Therapeutics appoints Willard Dere to Board of Directors

* Seres Therapeutics strengthens board of directors with appointment of Willard Dere, M.D., former Amgen Chief Medical Officer Source text for Eikon: Further company coverage:

BRIEF-Seres Therapeutics initiates ser-109 phase 3 study in patients with multiply recurrent c. difficile infection

* Seres Therapeutics initiates ser-109 phase 3 study in patients with multiply recurrent c. Difficile infection

BRIEF-Seres Therapeutics completes enrollment in early stage study of ulcerative colitis drug

* Seres Therapeutics announces completion of enrollment for ser-287 phase 1b study in patients with ulcerative colitis

BRIEF-Seres Therapeutics Inc Q1 loss per share $0.63

* Seres Therapeutics reports first quarter 2017 financial results and provides update on operational progress

BRIEF-Sarepta appoints Kenneth Fischbeckt to the company’s strategic and scientific advisory board

* Sarepta Therapeutics announces addition of Kenneth Fischbeck, M.D. And matthew wood M.D., Ph.D. to the company’s strategic and scientific advisory board Source text for Eikon: Further company coverage:

BRIEF-Seres Therapeutics files for mixed shelf of up to $150 mln

* Files for mixed shelf of up to $150 million - SEC filing Source text (http://bit.ly/2nJ2h2K) Further company coverage:

BRIEF-Seres Therapeutics to initiate new SER-109 clinical study

* Plans to initiate a new SER-109 phase 2 clinical study in patients with multiply recurrent clostridium difficile infection

BRIEF-Seres Therapeutics reports Q4 and full year 2016 financial results

* Seres Therapeutics reports fourth quarter and full year 2016 financial results and provides operational progress update

BRIEF-Seres Therapeutics announces key findings from SER-109 Phase 2 study analyses

* Seres Therapeutics announces key findings from SER-109 Phase 2 study analyses

BRIEF-Seres Therapeutics reports third quarter 2016 financial results

* Seres Therapeutics reports third quarter 2016 financial results and provides operational progress update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up